[
    [
        {
            "time": "2023-10-05",
            "original_text": "Livongo Bounces Back After Revenue Guidance Boost",
            "features": {
                "keywords": [
                    "Livongo",
                    "bounces back",
                    "revenue guidance",
                    "boost"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Livongo Bounces Back After Revenue Guidance Boost",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes",
            "features": {
                "keywords": [
                    "FDA",
                    "panel votes",
                    "Lilly",
                    "Jardiance",
                    "Type I Diabetes"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss",
            "features": {
                "keywords": [
                    "Celldex",
                    "Q3 loss",
                    "narrower",
                    "expected",
                    "revenues miss"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]